NCT04631107View on ClinicalTrials.gov

AD109 Dose Finding in Mild to Moderate OSA

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

AD109 dose1- A

Oral administration at bedtime

DRUG

AD109 dose2- B

Oral administration at bedtime

DRUG

Placebo- C

Oral administration at bedtime

Trial Locations (3)

19063

Brian Abaluck, LLC, Philadelphia

30328

NeuroTrial Research, Atlanta

92103

Pacific Research Network, San Diego

Sponsors

Lead Sponsor

Apnimed
All Listed Sponsors
lead

Apnimed

INDUSTRY